Table 1.
Schedule of enrolment, interventions, and assessments
| Study period | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Index procedure | ||||||||||||
| Enrolment | Allocation | Angioplasty | Post-procedure | Follow-up | ||||||||
| Timepoint | -t1a | -t2b | 0 | Immediately after allocation | Before discharge§ | 1-month ± 7 days Phone call |
6-month ± 30 days On-site |
12-month ± 45 days On-site |
24-month ± 60 days On-site |
36-month ± 60 days Phone call |
48-month ± 60 days On-site |
60-month ± 60 days Phone call |
| Enrolment | ||||||||||||
| Eligibility screen | X | |||||||||||
| Informed consent | X | |||||||||||
| Allocation | X | |||||||||||
| Interventions | ||||||||||||
| Intraluminal guide wire crossingc | X | |||||||||||
| Pre-dilatione | X | |||||||||||
| Sirolimus-coated balloon angioplasty | X | |||||||||||
| Paclitaxel-coated balloon angioplasty (control) | X | |||||||||||
| Assessments | ||||||||||||
| Demographic data | X | |||||||||||
| Physical examination | X | X | X | X | X | X | ||||||
| Laboratory examinationf | X | |||||||||||
| Medical history | X | |||||||||||
| Concomitant medication | X | X | X | X | X | X | X | X | X | |||
| Angiography | X | X | ||||||||||
| Duplex ultrasoundg | X | X | X | X | X | |||||||
| ABI | X | X | X | X | X | X | ||||||
| Rutherford category | X | X | X | X | X | |||||||
| Walking distance (participant self-assessmenth) | X | X | X | X | X | X | X | X | ||||
| VascuQuol Score | X | X | X | X | X | |||||||
| 6-min walk test | X | X | X | X | X | |||||||
| Treadmill test (optional) | X | X | X | X | X | |||||||
| EQ5D-3L index | X | X | X | X | X | X | X | X | ||||
| AE/SAE | X | X | X | X | X | X | X | X | X | |||
aAt baseline
bDuring index procedure
cSuccessful intraluminal guidewire crossing of the lesion
dWithin 2 working days after index procedure and before discharge
ePre-dilation without flow-limiting dissection
fIncluding pregnancy test were appropriate
gDUS should also be performed before and after any target vessel revascularization. Adjudication by core laboratory at 6, 12, and 24 months
hParticipant self-assessment of maximum walking distance should be performed before walk tests and questionnaires
AE adverse event, SAE severe adverse event